ProCE Banner Activity

CE / CME

Webcast: Precision Management of Late Endocrine Effects in Cancer Survivors

Multimedia
From ENDO 2021, learn how to look for and manage the many late endocrine effects of childhood cancer and its treatments, including hypothalamic pituitary dysfunction, thyroid disorders, obesity and diabetes mellitus.

Pharmacists: 1.50 contact hours (0.15 CEUs)

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Released: March 22, 2021

Expiration: February 28, 2022

No longer available for credit.

Share

Faculty

Wassim Chemaitilly

Wassim Chemaitilly, MD

Associate Member and Director
Director

Division of Endocrinology
St. Jude Childrens Research Hospital
Memphis, Tennessee

Laurie E. Cohen

Laurie E. Cohen, MD

Director, Neuroendocrinology Program
Director, Growth Program
Division of Endocrinology
Boston Children’s Hospital
Associate Professor of Pediatrics
Harvard Medical School
Boston, Massachusetts

Danielle N. Friedman

Danielle N. Friedman, MD, MS

Pediatric Long-Term Follow-Up Program
Department of Pediatrics
Memorial Sloan Kettering Cancer Center
New York, New York

Steven G. Waguespack

Steven G. Waguespack, MD

Professor
Division of Internal Medicine
Department of Endocrine Neoplasia and Hormonal Disorders
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by the Endocrine Society, in collaboration with Clinical Care Options.
ProCE Banner

Supporters

Supported by an educational grant from

Novo Nordisk Inc

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize the common root causes of late endocrine effects due to cancer treatment in survivors of childhood cancer and the importance of lifelong monitoring for their development
  • Review hypothalamic pituitary disorders in childhood cancer survivors
  • Apply practical strategies to diagnosing thyroid disease in pediatric cancer patients and survivors
  • Discuss the challenges of obesity and diabetes mellitus in cancer survivors

Faculty Disclosure

Primary Author

Wassim Chemaitilly, MD

Associate Member and Director
Director

Division of Endocrinology
St. Jude Childrens Research Hospital
Memphis, Tennessee

Wassim Chemaitilly, MD, has disclosed he has no relevant financial relationships during the content development process for this activity.

Laurie E. Cohen, MD

Director, Neuroendocrinology Program
Director, Growth Program
Division of Endocrinology
Boston Children’s Hospital
Associate Professor of Pediatrics
Harvard Medical School
Boston, Massachusetts

Laurie E. Cohen, MD, reported the following relevant financial relationship(s) during the content development process for this activity: Research Investigator, Pfizer, Inc.; Speaker, Novo Nordisk; Other, Sandoz

Danielle N. Friedman, MD, MS

Pediatric Long-Term Follow-Up Program
Department of Pediatrics
Memorial Sloan Kettering Cancer Center
New York, New York

Danielle N. Friedman, MD, MS, reported the following relevant financial relationship(s) during the content development process for this activity: Advisory Board Member, Fennec

Steven G. Waguespack, MD

Professor
Division of Internal Medicine
Department of Endocrine Neoplasia and Hormonal Disorders
University of Texas MD Anderson Cancer Center
Houston, Texas

Steven G. Waguespack, MD, has disclosed he has no relevant financial relationships during the content development process for this activity.

Instructions for Credit

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit

The Endocrine Society designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

For questions about content or obtaining CME credit, please contact the Endocrine Society at education.endocrine.org/contact.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

For questions about obtaining Nursing credit, please contact Sophia Kelley at skelley@clinicaloptions.com.

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-21-017-L01-P.

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Additional Information

Program Medium

This program has been made available online.